Development of hyaluronic acid–Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides

Kumar, Arun; Sahoo, Bishwabhusan; Montpetit, Alison; Behera, Sumita; Lockey, Richard F.; Mohapatra, Shyam S.

doi:10.1016/j.nano.2007.03.001

Cited by 95 publications

(59 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacokinetic properties, such as circulation time and biodistribution, are influenced by incorporating the targeting and cellspecific uptake properties of HA onto large carriers. Cargos delivered to CD44 over-expressing cells include anti-cancer drugs: epirubicin, 14 doxorubicin, 37,38,41,69,70,71 paclitaxel, 28,29,62,63 and mitomycin c, 14,70 as well as agents such as siRNA, 72 iron oxide magnetic particles, 73 and DNA. 74 These studies are summarized in Tables 3 and 4. Several different methods have been used to improve the distribution of doxorubicin, which has significant cardiotoxicity as a free drug.…”

Section: C Hyaluronan In a Targeted Nanocarrier Systemmentioning

confidence: 99%

Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, a Hyaluronan Receptor

2008

View full text Add to dashboard Cite

The complex system involved in the synthesis, degradation, and binding of the high molecular weight glycosaminoglycan hyaluronic acid (hyaluronan or HA) provides a variety of structures that can be exploited for targeted cancer therapy. In many cancers of epithelial origin there is an up-regulation of CD44, a receptor that binds HA. In other cancers, HA in the tumor matrix is over-expressed. Both CD44 on cancer cells and HA in the matrix have been targets for anti-cancer therapy. Even though CD44 is expressed in normal epithelial cells and HA is part of the matrix of normal tissues, selective targeting to cancer is possible. This is because macromolecular carriers predominantly extravasate into the tumor and not normal tissue; thus CD44-HA targeted carriers administered intravenously localize preferentially into tumors. Anti-CD44 antibodies have been used in patients to deliver radioisotopes or mertansine for treatment of CD44 expressing tumors. In early phase clinical trials, patients with breast or head and neck tumors treated with anti-CD44 conjugates experienced stabilized disease. A dose-limiting toxicity was associated with distribution of the antibody-drug conjugate to the skin, a site in the body with a high level of CD44. HA has been used as a drug carrier and a ligand on liposomes or nanoparticles to target drugs to CD44 over-expressing cells. Drugs can be attached to HA via the carboxylate on the glucuronic acid residue, the hydroxyl on the Nacetylglucosamine, or the reducing end which are located on a repeating disaccharide. Drugs delivered in HA-modified liposomes exhibited excellent anti-tumor activity both in vitro and in murine tumor models. The HA matrix is also a potential target for anti-cancer therapies. By manipulating the interaction of HA with cell surface receptors, either by degrading it with hyaluronidase or by interfering with CD44-HA interactions using soluble CD44 proteins, tumor progression was blocked. Finally, cytotoxic drugs or pro-drug converting enzymes can be attached to the HA matrix to generate a cytotoxic fence around the tumor. This review describes how the complex interplay among cancer biology, the CD44-HA interaction, drug carriers and drug targeting has been used to improve anti-cancer therapies. As these approaches evolve, they hold forth the prospect of significantly improved targeted anti-cancer treatments. KeywordsAntibody; Biodistribution; Cancer; Chemotherapy; Drug-conjugate; EPR effect; Liposome; Polymer; Prodrug; Recombinant Protein The Biology of the CD44-Hyaluronan InteractionHyaluronan (HA) (Figure 1) is a high molecular weight glycosaminoglycan, extracellular matrix component essential for proper cell growth, organ structural stability, and tissue organization. The amount of HA in a tissue depends upon on a complex interplay among HA synthesis by HA synthases, 1 HA internalization by cell surface receptors, 2 Interference with the CD44-HA interaction by either targeting drugs to CD44, 14 targeting drugs to the HA matrix 15 or interfering with HA ma...

show abstract

Section: C Hyaluronan In a Targeted Nanocarrier Systemmentioning

confidence: 99%

Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, a Hyaluronan Receptor

2008

View full text Add to dashboard Cite

show abstract

“…Simultaneously, change in complex size before and after BSA addition (final concentration of 10 mg/mL) was measured soon. Each sample was measured in duplicate at least three times at room temperature (Kumar et al, 2007) and the complexes prepared for zeta potential measurement did not include salts.…”

Section: Characterization Of Ha/pei/dna Complexesmentioning

confidence: 99%

Positive hyaluronan/PEI/DNA complexes as a target-specific intracellular delivery to malignant breast cancer

Sun

Cao

et al. 2009

Drug Delivery

View full text Add to dashboard Cite

“…10 Another example of the use of hyaluronic acid, to target cells and tissues delivering peptides, comes from a study using hybrid nanoparticles containing hyaluronic acid and iron oxide which showed high efficiency due to highly specific targeting of CD44, a hyaluronic acid binding receptor found on the surface of tumor cells and inflammatory cells. 11 In the field of ocular drug delivery, hyaluronic acid has been used to modify chitosan nanoparticles, indicating that it might enhance their mucoadhesiveness and efficiency. 12 With regard to the effect of hyaluronic acid on inflammatory mediators, immune cells, and oxidative stress, it has been observed that hyaluronic acid produces a low-grade inflammatory response when it stimulates peripheral blood mononuclear cells.…”

Section: Hyaluronic Acid and Nanomedicinementioning

confidence: 99%

Probable biofilm formation in the cheek as a complication of soft tissue filler resulting from improper endodontic treatment of tooth 16

Marusza

Młynarczyk²,

Olszański³

et al. 2012

IJN

View full text Add to dashboard Cite

Injectable filling agents offer the promise of a better appearance without surgery and, among them, hyaluronic acid is the most commonly used. Although complications are rare, it is necessary to know the possible side effects and complications in order to be prepared for their management. That is why many researchers have been focusing on the interactions between hyaluronic acid and pathogens, inflammatory mediators, the immune system, and markers of oxidative stress to achieve efficient drug delivery, given that hyaluronic acid has widening applications in the field of nanomedicine. Here we report the case of a 37-year-old female patient who returned to our clinic with an abscess in her left cheek 3 months after a deep injection of 1 mL of stabilized hyaluronic acid in both cheeks. Steroid and antibiotic therapy was initiated without success, and abscess drainage was performed. Extraction of tooth 16 was performed 11 days after insertion of drains into the abscess. Laboratory blood tests showed acute inflammation of presumed bacterial etiology. Microbiological examination of pus was negative. Bacterial cultures were found in the extracted tooth. After antibiotic therapy, a complete reversal of the pathological process was observed. The present report highlights the need to assess periodontal problems prior to any aesthetic facial treatment. Analyses of further case reports and clinical studies are necessary to understand the potential role of hyaluronic acid in the formation of biofilm, and how to avoid this complication, thereby increasing the safety of hyaluronic acid-based procedures.

show abstract

Development of hyaluronic acid–Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides

Cited by 95 publications

References 22 publications

Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, a Hyaluronan Receptor

Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, a Hyaluronan Receptor

Positive hyaluronan/PEI/DNA complexes as a target-specific intracellular delivery to malignant breast cancer

Probable biofilm formation in the cheek as a complication of soft tissue filler resulting from improper endodontic treatment of tooth 16

Contact Info

Product

Resources

About